Thymic carcinoma arises from acquired somatic changes in thymic epithelial cells. No inherited genetic cause or Mendelian inheritance pattern has been established. Risk factors are poorly characterized due to the rarity of the condition. Unlike thymoma, thymic carcinoma is not typically associated with autoimmune paraneoplastic syndromes such as myasthenia gravis.

Diagnosis requires histopathological examination of tumor tissue obtained by biopsy or surgical resection. CT and MRI imaging define the extent of disease and detect distant spread. Staging follows classification systems established for thymic epithelial tumors, and distinguishing thymic carcinoma from thymoma and other mediastinal malignancies is essential for treatment planning.

Surgical resection is preferred for localized, technically resectable disease. Chemotherapy is used for locally advanced or metastatic disease, in both neoadjuvant and palliative settings. Radiation therapy contributes to local control, particularly after surgery. No FDA-approved drugs are specifically indicated for thymic carcinoma; one agent holds orphan drug designation for thymoma and thymic carcinoma and is under investigation.

Prognosis is less favorable than for thymoma due to the aggressive disease course. Outcomes depend on stage at diagnosis, completeness of resection, and response to systemic therapy. Advanced disease carries a more guarded prognosis. Management at specialized centers with multidisciplinary expertise is recommended.

More than 20 clinical trials are registered for thymic carcinoma and related epithelial tumors, evaluating neoadjuvant chemotherapy strategies, checkpoint inhibitor combinations, and novel targeted agents. Research is complicated by the rarity of the diagnosis and frequent pooling with thymoma in study designs.